Frazis Capital Podcast: Recent Episodes
Michael Frazis
It must be a uniquely modern horror to see a drone flying towards you with a grenade strapped, and it must be all the worse to know your last moments are being filmed.
Drones are now ubiquitous across the battlefields of Ukraine, Gaza, and shipping lanes in the Middle East. Costing relative pittances, cheap drones loaded with explosives can destroy military hardware worth millions, or in the case of ships, billions of dollars.
They can combine in swarms to overwhelm even the most advanced defence systems, and mask deadlier missiles and weaponry.
This new asymmetry has changed the battlefield, so it was timely to sit down with Oleg Vornik, CEO of Droneshield, to discuss how their technology can detect and disable these deadly low-cost swarms.
There are handheld versions sold to soldiers and spies, larger systems for tanks and ships, and larger systems still with a broader range of senses for airfields, bases, and civilian sites like prisons and airports.
Drones can be shot down with guns, caught in a net by other drones, or destroyed by high-tech lasers and microwaves. Droneshield specializes in defending against cheap drones that are causing so much havoc by jamming their communications and forcing them down.
With the world seemingly in flames it’s not surprising that Droneshield’s growth has been explosive. Revenues jumped from $17m in 2023, to $55 million in 2024, and could reach over $90 million in 2025.
The opportunity is substantial, perhaps less than 1% penetrated globally, as most military units around the world are entirely undefended.
Detection and monitoring is playing an increasing part of Droneshield's business, as their software can track and monitor drones across an entire battlefield.
The civilian opportunity is perhaps even greater.
Drone sightings closed Gatwick airport for three days in December 2018, and the perpetrators were never discovered. Prisons, powerplants, architectural sites like Sydney Opera House are exposed.
I personally know people who have seen drones flying over their homes, and are concerned these could be theives testing whether anyone is in, or God forbid, photographing children.
There's a good chance within a few years that anti-drone technology is as ubiquitous as drones themselves are today, and Droneshield is particularly well positioned given its ability to defend against commercially available models that can be bought in-store in all major cities and ordered online from Amazon and Alibaba to almost anywhere in the world.
Oleg shared some fascinating anecdotes around their use in the military, prisons, and when Droneshield's technology defended political leaders from attack.
I'm sure you'll find this conversation as interesting as I did!
Michael
Timestamps
0:03 – Oleg introduces DroneShield
1:02 – How it works
2:10 – Autonomous drones and AI on the modern battlefield – how Droneshield fits in
11:02 – Droneshield’s products
22:16 – Additional use cases for DroneShield products
23:37 – The different ways to destroy a drone
30:49 – Future of drone warfare and Droneshield’s product pipeline
37:55 – Partnering with US and Australian defence agencies
43:36 – The civilian opportunity, prisons, airfields, stadiums
49:00 – Manufacturing of DroneShield products
50:46 – Financial overview and the investment case
-
Clarity Pharmaceuticals Success:
- Clarity Pharmaceuticals reported a significant response in a patient with metastatic castrate-resistant prostate cancer.
- The patient received two cycles of copper 67 Biss. PSMA, and after six months from the second dose, there was no evidence of PSA, indicating a potential cure.
- This is noteworthy because the patient had undergone extensive prior treatments, including chemotherapy and androgen deprivation therapy.
-
Trial Progress and Market Potential:
-
Clarity Pharmaceuticals has been releasing data as each cohort progresses in their trial, currently in the fourth cohort of phase one.
- The market potential for effective prostate cancer treatment is significant, estimated at over $6 billion.
- The company's stock is trading at around $650 million, with considerable interest from both investors and pharmaceutical companies due to the promising trial results.
-
Director Confidence and Financials:
-
Directors have shown confidence in the company by purchasing stock with cash, signaling belief in the company's prospects.
- Clarity Pharmaceuticals has a substantial cash reserve of $150 million AUD, providing a strong financial position for future trials and developments.
-
Curve Beam AI Progress:
-
Curve Beam AI reported progress with six device sales and orders for five more devices in one month, indicating a potential annual run rate of 60.
- The company is working on expanding its device's approved usage beyond foot and ankle to include hip and knee, which could significantly increase its market potential.
-
Financial Challenges and Future Prospects:
-
Curve Beam AI faces financial constraints with approximately $11.8 million in cash, expecting to last until September 2023.
- The company's success relies on increasing its installed base to maximize revenue from software updates and future developments.
-
Trans Medics' Strong Performance:
-
Trans Medics reported a 133% increase in revenue compared to the previous year, with $12 million in net income for the quarter.
- The company's profitability amidst significant revenue growth highlights the effectiveness of its platform and pricing power.
-
Market Trends and Risk Management:
-
Market trends show a divergence between companies with strong performance like Trans Medics and those with weaker results like AMD.
- Applying quantitative risk management strategies can reduce drawdowns and optimize returns, as demonstrated by Trans Medics' performance.
-
Comparison with AMD:
-
AMD reported declines in gaming and embedded segment revenue, highlighting the importance of sticking with market leaders like Nvidia.
- Nvidia's consistent growth and profitability contrast with AMD's weaker financial performance, emphasizing the benefits of choosing market leaders.
-
Conclusion:
-
The podcast concludes with reflections on the updates from Clarity Pharmaceuticals, Curve Beam AI, Trans Medics, and AMD, highlighting the importance of strategic investment decisions and risk management strategies in navigating the market.
Bond yields hit cycle highs, medtech takes a GLP-pounding, Nvidia and Microsoft do some cool science, and all roads in semiconductors lead to TSMC.
Double or Nothing #16: Qantas scandal, an aggressive move in capital markets, a new IPO, and dodgy Government energy data.
0:12 – Latest (deflationary) inflation data
6:42 – Investing strategies
10:30 – Tesla’s journey and the switch to self-driving capabilities
12:56 – David Walsh’s presentation at Sohn Conference on professional gambling
14:46 – Grindr IPO
21:36 – Recap of Blackbird’s Sunrise startup conference and thoughts on private markets
31:44 – Lessons learned from market downturns
38:25 – Cyclicality of the semiconductor industry
39:31 – Life science industry outlook
Double or Nothing with Michael Frazis and Misha Saul.
Adobe buys Figma, Ancient and Modern heroes, and CPI prints
0:32 – Passing of Queen Elizabeth II
7:35 – Kim Kardashian’s new private equity play
9:16 – Collapse in price of crude oil
13:12 – Market and inflation outlook
15:32 – Twilio
21:19 – Whitehaven Coal
24:37 – Update on VC Fund deals
32:02 – Summary and wrap-up
Double or Nothing with Misha Saul and Michael Frazis
0:15 – Preview and thoughts on Jerome Powell’s upcoming speech
1:00 – Update on Nvidia’s recent earnings and the wider semiconductor industry
12:10 – Farfetch update and latest earnings
15:45 – Notable small cap and GARP stocks
17:23 – Qantas recent performance and share buyback announcement
22:46 – Nathan Tinkler’s proposed coal mine acquisition
26:31 – Texas government order for divestment of all Blackrock holdings due to hostility on fossil fuels
28:06 – Andrew Forrest’s rise in the mining industry
34:05 – Assessment of Farfetch’s success and outlook
38:15 – Cettire – ASX listed Australian luxury goods company
42:19 – Rise and fall of Marley Spoon
49:20 – Summary and wrap-up
An interview with Dr Stephen Tisch, who is researching treatment methods for dystonia at St Vincent's Hospital, Sydney.
If you would like to support Neurology and Neurosciences Research at St Vincent’s please visit www.supportstvincents.com click Donate, and select 'Neurosciences Research' from the drop-down menu.
Or contact Nicole at the St Vincent’s Curran Foundation on +61 422 715 377 or by Email nicole.forrestgreen@svha.org.au for EFT-bank details and cheque instructions.
Michael Frazis reviews the market.
1:35 – Fallen angels & Fed balance sheet taper 3:53 – Comments on Coupa 7:26 – Lightspeed 8:35 – Teladoc 13:15 – Twilio 14:40 – Roku 18:10 – Upstart 19:16 – EBR Systems 20:40 – PayPal and Visa 24:52 – Coupang 29:50 – Thoughts on inflation 31:46 – Question #1: Sea Limited 32:12 – Question #2: Comments on mid-cap growth companies that haven’t fallen 32:42 – Question #3: Portfolio outlook 36:22 – Question #4: Crypto for payments 38:07 – Question #5: Matterport 38:45 – Question #6: Additional question on Upstart 39:33 – Question #7: Comparison of current revenue multiples to early 2000’s 43:40 – Question #8: Update on Regeneron and the Biotech sector 47:51 – Question #9: PayPal vs. Square
1:00 – Thoughts on the recent inflation data from the US 3:06 – The 6% differential between the Fed funds rate and inflation, and its impact on the economy 4:31 – Parallels with inflation spikes in the seventies and nineties 7:36 – The effect of inflation on the Australian dollar 7:46 – The effect of inflation on companies – Cloudflare 9:00 – Comments on Lightspeed 9:43 – Comments on Cettire 10:27 – Comments on Upstart 15:35 – Thoughts on Opendoor’s recent results and Zillow’s exit 17:47 - Roblox’s continued explosive growth and its impact on the Metaverse 19:05 – Thoughts on MercadoLibre’s recent results 19:59 – Our number one pick in the crypto space – Galaxy Digital 21:07 – Two crypto coins that you can stake – Olympus and KlimaDAO 22:39 – Question #1: What is the impact of credit risk on companies like Upstart during economic downturns? 23:41- Question #2: Thoughts on Paypal? 24:28 – Question #3: Thoughts on DermTech’s recent quarterly? 25:37- Question #4 Thoughts on Marqeta? 25:55 – Question #5: Thoughts on Quantum-Si? 26:35 – Question #6: Have you ever owned Trade Desk? 27:22 - Question #7: What do you think of Fulgent Genetics? 28:30 – Question #8: Thoughts on Green Hydrogen? 30:14 – Question #9: Do you still hold and believe in TIGR/FUTU? 32:04 – Question #10: What’s the outlook on India for the next 5-10 years? 32:49 – Question #11: What platform do you use to purchase your crypto?
0:58 Launch of our Venture Fund
3:04 The benefits of pre-IPO access and our investment in Camplify
4:58 Private access to fast growing companies like Mawson Infrastructure
6:05 Zillow’s shrinking growth model
11:05 Comparative management decisions between Opendoor and Zillow
15:54 More on Zillow’s travails and management
17:29 The importance of customer love – Tesla
18:25 Tesla valuation thoughts
19:16 The NFT and crypto revolution
23:40 How crypto is transforming how games are played
27:48 Facebook’s lame Metaverse
29:53 The exciting prospects of games like Star Atlas
30:55 Our thoughts on Pinduoduo and Coupang
31:47 Chinese capital controls and its effects on FUTU and TIGR
33:44 What we like about Solana
34:24 The investment bank of the crypto world – Galaxy
35:50 Value in holding crypto companies – Voyager Digital
Q&A’s
36:30 Question: Would love to here your thoughts on FUTU?
37:03 Question: What’s the upside of Tesla’s valuation?
38:17 Question: Thoughts on great resignation and how work is changing?
39:40 Question: What are your thoughts on Zoom?
40:00 Question: Do you like Sandbox over MANA?
40:20 Question: Opening fund for retail?
40:28 Question: Thoughts on Paradigm Pharma?
42:00 Question: What are your thoughts on Chegg?
44:00 Question: What are your thoughts on Allbirds?
44:18 Question: Thoughts on inflation?
45:10 Question: Thoughts on Iris energy?
46:30 Question: CBA and crypto trading?
48:35 Question: What is the global gaming TAM and growth rate?
50:17 Criminal coins
Henry joins us to talk about his journey and experiences with surface science, engineering, and the US Airforce.
Timestamps
0:35 – How did MicroTau come to be?
2:08 – Henry discusses his involvement with InnoCentive challenges
5:16 – A challenge from the US Air Force Research Laboratory
6:26 – What is drag?
8:26 – How riblets found on shark skin can reduce drag
11:20 – Printing with light to create nano-scale features on surfaces
15:14 – Henry talks about his unexpected success with the US Air Force challenge
17:54 – Submitting a business proposal to the US Air Force
19:47 – The process of implementing the technology
22:13 – The carbon and cost savings associated with reducing friction drag on large-scale aircrafts
24:04 – The applications of MicroTau’s technology
27:18 – How the product will scale to large-scale surfaces
28:37 – MicroTau’s revenue model
30:35 – The process of approval in a highly-regulated industry
32:45 – MicroTau’s funding sources
33:30 – Support for start-ups in Australia
35:27 – What are some of the other applications for these riblets?
40:37 – Different types of surfaces and their applications
41:11 – Gecko pads
43:08 – Optical applications including visual adaptive camouflage
46:00 – Namib beetles
47:08 – What’s next for MicroTau?
48:48 – Growing the team
50:02 – MicroTau’s first active flight test this year
Michael Frazis gives an update and answers questions.
0:26 – Introduction
1:10 – Performance update
1:58 – Comments on the NASDAQ100’s strong rally
2:46 – The performance of small-mid cap companies
3:38 – An analyse of where our returns have come from over the years
4:20 – Our past investment in bluebird bio
5:39 – Our IPO/pre-IPO investments in the life sciences
6:57 – We funded a PhD fellowship on research into Dystonia
8:45 – True customer love and explosive growth
9:14 – Our take on ESG and the rising coal prices
10:40 – The effects of currency fluctuations on a fund’s performance
12:23 – Drivers in the value of the AUD
13:36 – Comments on Opendoor and the three industries that are resistant to ecommerce
16:25 – Comments on Upstart
18:42 –Thoughts on the decline in digital health companies
20:03 – Question #1: What do you think of PointsBet?
21:31 – Question #2: Do we still hold Guardent and Dermtech?
23:30 – Question #3: The contribution of the life science companies to the fund’s performance
26:08 – Question #4: Are you planning on taking advantage of the current dip in the market?
26:23 – Question #5: What are the risk management strategies when if the market turns?
28:51 – Question #6: Customer love in the life sciences
29:09 – Question #7: How has the recent move back into China-tech progressed?
30:12 – Question #8: What do you think of developer tools ecosystem DevOps?
30:51 – Question #9: What is an odd stock that looks good at the moment? (Camplify and Cettire)
31:35 – Question #10: What are your thoughts on Megaport?
31:50 – Question #11: What are your thoughts on cloud in general? (Snowflake)
32:58 – Question #12: Do you see the fund’s China positions as trading or long-term holds? (Pinduoduo)
36:25 – Question #13: Would eye-wear replace mobiles?
37:20 – Question #14: What are your thoughts on the recent Canva valuation?
40:18 – Question #15: What are your thoughts on Fiverr?
Timestamps
0:15 Introduction to our strategy
2:55 How a company can lose money and still create value
4:38 Avoiding ‘deep value’ traps
5:30 Update on 2021 fund performance
6:50 How we’re investing in China
9:00 Update on FUTU’s Q2 results and why we bought more
12:18 Recently approved antibodies for COVID-19 – cause for optimism?
16:23 Update on Cettire’s FY21 results
18:03 How we evaluate business ‘quality’
19:00 Update on Camplify’s FY21 results
21:18 Question: thoughts on Digital Turbine
22:39 Question: thoughts on the recent Square and Afterpay deal
Michael Frazis describes his investment company’s strategy that involves a 30-40 year view, not panicking and diverting the approach during dips and rallies. Evaluating growth stocks involves identifying customer love for a product or service which acts a key indicator of explosive growth potential. This approach is utilized in picking winners in industries like the ‘buy now, pay later’ space. Frazis explains how vaccine development is a long process involving extensive trials and how the emergency approval of Moderna’s vaccine allowed the company to prove the mRNA concept, providing the company a significant boost.
TIMESTAMPS
0:00 - Intro and background
2:39 - Founding his company at 29 and investing strategy
11:38 - Evaluating polarizing stocks like Tesla
15:08 - Investing psychology
18:45 - Processing investment information
23:17 - Investing in industry creators
25:31 - Moderna and life sciences investments
31:43 - Dogecoin case study
35:30 - Growth stocks amid inflation
Michael Frazis attempts to understand the FDA's decision to approve Biogen's aducanumab for Alzheimer's and the possible ramifications.
Timestamps · 0:32 – Our fast-growing portfolio companies · 2:21 - Frazis life sciences strategy update · 5:18 – RNAi Biology · 7:15 – Alnylam: RNAi clinical development pipeline and recent execution · 8:16 – Timing and valuation in life sciences · 9:26 – What do we think of CRISPER? · 11:03 – Companies targeting sickle cell disease · 11:56 – Companies targeting beta-thalassemia · 12:53 – Platform technologies: Moderna · 15:12 – Platform technologies: Ultragenyx · 16:30 – Special focus: Alzheimer’s · 18:50 –Alzheimer’s APOE4 · 23:50 – Could Alzheimer’s be caused by infection? · 24:55 – Cortexyme: Alzheimer’s and the gingivalis hypothesis · 27:00 – Cassava and Alzheimer's · 28:30 – How are we different to Ark? · 29:10 – Summary
Dr. Robert Stretch is a specialist in Pulmonary, Critical Care & Sleep Medicine.
After graduating from Yale School of Medicine in 2014, he completed subspecialty training at BIDMC, a Harvard teaching hospital in Boston, and UCLA Medical Center in Los Angeles.
Timestamps
0:05 – Introducing Robert Stretch
0:25 – Robert’s journey studying medicine in the US
3:40 – Findings when working on the MIMIC (Medical Information Mart for Intensive Care) database at MIT University
9:31 – Robert’s move into sleep apnoea
12:23 – What is sleep apnoea?
16:47 – What are the main risk factors for developing sleep apnoea?
17:26 – What is the current standard of care for sleep apnoea?
18:26 – Working in US ICU’s remotely from Sydney
23:11 – The need for remote ICU doctors
26:00 – Robert’s experience treating Covid patients in ICU
31:58 – Why are older people more vulnerable to Covid-19?
33:19 – Assessment of the Australian government’s Covid-19 support and vaccine distribution
40:30 – Outlook on Australian biotech companies
46:52 – What is RNAi technology?
52:40 – Pricing of vaccines and antibiotics globally
59:04 – Link between Alzheimer’s and Gingivitis
0:15 – Introduction to Frazis Capital Partners.
1:45 – Sell-off trends and SPAC’s.
3:57 – Growth stocks outperforming tech indices.
6:45 – Standpoint on growth stocks.
9:18 – Software’s strong run.
11:05 – Multiple contractions and what this means.
13:30 – Teladoc Health.
14:20 – View on Appharvest.
16:45 – Batteries & developments in the lithium space.
18:30 – Thoughts on DermTech.
19:58 – Chinese regulatory risks.
22:29 – What is a stock?
24:15 – State of play for Xero.
25:25 – What do we look for in a company?
27:00 – Are we currently buying?
28:21 – Thoughts on the Redbubble quarterly results.
30:12 – Outlook on Airtasker.
31:00 – Our current best stock play.
32:24 – Perspective on Coinbase.
34:40 – Key takeaways/Summary.
Brian Hartzer joins us to talk about his new book 'The Leadership Star', available from Amazon.
Brian was CEO of Westpac from 2014-2020. For those who don't know Westpac is Australia's second largest bank with over $800 billion of assets.
Brian discusses his 'Leadership Star' framework and pivotal moments in Australia's banking history. Brian also shares his views on cryptocurrency, neobanks, alternative lenders, the Buy-Now-Pay-Later movement, and the future of financial technology more broadly.
Timestamps
00:05 – Introducing Brian
03:15 – Brian's new book: ‘The Leadership Star: A Practical Guide to Building Engagement’
06:00 – Shifting from management consulting to running ANZ’s credit card business
08:25 – Brian’s perspective on the evolution of credit cards in Australia
10:25 – The five c’s of leadership: care, context, clarity, clearing the way and celebrate
11:05 – Why the phrase ‘I’m just a teller’ is a sign of bad management
13:00 – Why cleaners are the most important workers at Disney
14:10 – ‘Clearing the way’ - what does this mean?
15:50 – How corporate and leadership culture has changed over Brian’s career
18:46 – How Brian navigated the “biggest bank failure in history”
20:25 – What led to the downfall of RBS
23:37 – Brian’s perspective on the evolution of US corporate culture
24:50 – The state of banking technology in the UK
28:58 – Why more competitors doesn’t necessarily equal better consumer outcomes
29:17 – How the banking landscape helped Australia navigate the GFC
31:35 – Behind the scenes of the Australian banking crisis in 1991/1992
32:58 – Why hybrid bank branches are the way of the future
36:15 – Multi-brand strategies and Westpac
39:30 – Brian’s thoughts on the buy-now-pay-later sector
42:28 – Will the buy-now-pay-later sector will displace credit cards?
44:58 – Views on Bitcoin and why Brian pushed through Westpac's investment in Coinbase
49:20 – The “one and only legitimate” use case for bitcoin
50:50 – The future of neobanks and alternative lenders
54:15 – Predictions on the future of banking technology
55:45 – Brian’s pivot to working as an angel investor
57:50 – The one key takeaway from Brian’s new book
Michael Frazis gives an update on SPACs, rising interest rates, tech valuations and what might happen next.
Timestamps
1:35 - Quick review of 2021
2:30 - Thoughts on Cathie Wood and ARK
3:59 - Expansions and contractions in software multiples
7:40 - Snowflake
8:47 - SPACs: why we like them and why they're dangerous (hint: the same reason)
12:02 - Why we hope SPACs encourage leading tech firms to list sooner
14:21 - Dodgy forecasts
16:51 - Why we rule out most SPACs in the fund
18:00 - Navigating rising interest rates
22:33 - The recent sell-off
24:32 - How we look at market rotations
26:46 - Coupang IPO
January 2021 - one of the more amusing weeks of finance.
0:57 - The short squeeze
2:31 - The reality of Robinhood's 'free' trades
5:08 - The hidden consequences of Hedge Fund strategy
6:51 - How useful is management access?
9:56 - The gamma squeeze
12:15 - How this forced people to rethink how they discuss finance?
13:39 - Is the squeeze squoze?
14:37 - Timing and recovery
15:40 - Our strategy
17:24 - An important dynamic of short interest
19:43 - The true signal of growth
20:32 - How fund managers missed a multidecade trend?
23:00 - A changing guard in allocation decisions
1.40 - Quick review of 2020
2.35 - How to survive huge market swings like March 2020 and 2008-2009
3.45 - Discussion on support mechanisms in place in equity markets (central banks, fiscal stimulus, actions by management teams, etc)
5.45 - Current investment strategy is to stay invested & make sure we are constantly holding winners
7.35 - Sound fundamental reasons why companies with intense customer love, explosive growth, and market leadership perform so well
8.15 - Our companies are investing heavily. When revenue comes in they open new offices, hire marketing staff and etc which promises a greater return on investment. Many categorise these investments as costs, which gives the opposite (incorrect) answer
10.17 - Investment in tech and the "companies of the future" requires long term investment with value creation over 5 - 10 years
11.50 - Question: Have you invested in Nio? Nio capitalises on the necessity of an electric China. There is demand in the Chinese economy with issues like pollution for electric vehicles and the vast majority of the population will be buying locally made vehicles. Nio is a 100%+ revenue growth company and has proven user base in China
13.25 - Question: When do we trim? Focus of maintaining diversified portfolio of ultra-high growth companies
14.25 - Long term goals of the fund
16.17 - Question: Is there a limit to when printing to support the economy triggers inflation? Austerity weakened the private sector as seen in the UK and saw mass unemployment 17.14 - Comparison with the Australian experience
18.08 - The Greek experience with austerity, and how growth can be the solution to an economic crisis 20.20 - Worries around debt overhang have been consistently proven wrong for countries like Australia, Japan, UK and USA anyway
20.50 - Question: How are you investing in the life sciences? 22.23 - Discussion on liquid biopsy and Dermtech's sticker approach to melanoma 24.00 - Question: What do we think about SPACs?
26.20 - Question: what didn't work in 2020? A few biotechs underperformed, like Avita
27.40 - Discussion on Moderna now that vaccine is approved
30.33 - Market outlook: Market is changing with stimulus, vaccines and substantial changes in leadership with low interest rates
30.45 - At the highs of January 2021 we aim to stay consistent & ensure our portfolio companies are adding users and revenues everyday at the highest possible rates, just as we did in the lows
33.10 - Question: What do we think of high quality but richly priced companies like Crowdstrike?
33.23 - 2021 focus on life sciences - the space is independent over the growth space & captures novel explosive growth
34.10 - Always searching for companies that grow 100% year on year, trading on five-time sales
34.25 - Why we never bought Spotify
35.10 - Question: Are we in a tech bubble?
44.30 - Conclusion: we remain focused on our diversified portfolio of ultra-high growth companies intense customer love, long term
Jackie Vullinghs @ Airtree
0:11 - Introducing Jackie
0:54 - University in Australia vs the UK
3:08 - Interviewing at Oxford and Cambridge
3:56 - Approach to VC interviews with company founders
5:55 - Jackie discusses AirTree's key portfolio focus (digital health, fintech, consumer)
6:48 - Companies are staying private for longer, is that good or bad?
8:38 - How sustainable are the accelerations of digital health and ecommerce?
9:57 - Low relative penetration of ecommerce in Australia
11:25 - Equity derivatives in London
13:39 - Jackie's shift to start-up, Listable, Kalo
14:50 - August tech runup & option trading
20:46 - Alex Danco: are founders allowed to lie when selling a vision?
21:58 - Short reports and long-term growth of heavily shorted companies
24:27 - Interviews are a valid test for start-up hopefuls
26:14 - Creative arts and consumer tools to monetise creative pursuits
27:58 - Online writing & Jackie's substack (https://jax.substack.com/)
31:00 - As a collective, do retail investors make money?
33:03 - Snowflake IPO
34:26 - A Cloud Guru
37:15 - B2B SaaS playbook
39:08 - Jackie discusses AirTree
40:19 - The rise of new VC funds
41:45 - Listed vs. unlisted companies
42:50 - Comparing investment memos
45:08 - Customer love, competition and growth
49:16 - Pricing and flexibility of managed funds
51:26 - External descriptions of market shifts
52:21 - Spaceship voyager & superannuation
55:33 - Real Estate investment
Jarred Shein joins us to talk digital health. Jarred has invested in digital health at MH Carnegie and Qure, an Israeli based VC fund.
0:20 - Introducing Jarred
1:00 - Jarred's education and background.
1:45 - Jarred's studies of nanotechnology, specifically biochemistry
2:30 - Jarred's thesis on biosensor devices and how it relates to Startrek
3:55 - End of university job with Macromatix, completely unrelated to biochemistry
5:10 - The early opportunity to pick up distressed medical device assets
6:00 - Australia's strong position in the world and relatively painless COVID-19 experience make it a great place for global healthcare
8:10 - Australia's unfortunate lack of a biochemistry talent pool
9:30 - Australia's amazing history of medical device companies, including Cochlear and Resmed
10:30 - The opportunity to invest in the digital health space in Australia
11:40 - Deep dive into Resmed (RMD:ASX) and its successful pivot to health data revenue
14:40 - The benefits of living and doing business in Australia
16:33 - The rise and rise of telehealth services, silencing industry doubters
18:50 - 'Ageing in Place' (getting older comfortably in the environment that you are in) is a really interesting growth space
21:25 - 'Digital Therapeutics' (clinically relevant personal solutions) is another compelling growth area (e.g. Propeller Health - a recent Resmed acquisition)
25:00 - Discussion of Click Therapeutics (digital therapeutics solutions for mental health issues)
26:55 - What happens when the 20 year patent life timer ends?
27:50 - Jarred's thoughts on Livongo (NASDAQ:LVGO), a Frazis Capital position
30:30 - Successful US healthcare business models rely on the US health insurance system
32:00 - The merger between Teladoc (NYSE:TDOC) and LVGO
34:00 - There should be a very tight communication channel between primary care and chronic disease management
35:25 - Do you book a telehealth consultation based on Brand? Doctor? Or Price?
37:30 - Today's best opportunities in digital health, both listed and unlisted
38:50 - Missed opportunity in American Well (NYSE:AMWL), a hot recent digital health IPO
40:10 - Lots of opportunities in the private space for digital health
40:45 - Early stage Australian digital health companies can only access capital by going public
41:35 - Jarred discusses a compelling Australian microcap digital health opportunity, Hera Med (ASX:HMD)
43:40 - Jarred introduces an interesting QLD telehealth service provider called Medicine, providing remote primary care services
45:00 - Some problems within the digital health industry - access to capital and talent, commercialising technology
Sam Rich joins us to talk security, Crowdstrike, travel names, and how we're positioning the portfolio.
We discuss the current landscape and a couple of choice earnings reports.
0:20 – Introducing Joel Tomaino
1:10 – The structural shift to e-commerce
1:30 – Government stimulus and the diverse impacts of the current economic crisis
2:30 – How long will stimulus benefits and exacerbated e-commerce growth rates last
3:30 – Australian e-commerce plays, including Redbubble (ASX:RBL)
4:40 – E-commerce growth in mature markets compared to developing markets
5:00 – The opportunity for MercadoLibre (NASDAQ:MELI) in South America
6:20 – The opportunity for Sea (NYSE:SE) in South-East Asia
6:55 – Disney’s powerful platform and the success story of Disney Plus
8:25 – Is there pent up demand in travel? Will travel companies have their best years yet?
9:50 – Broader rotations in the market. Re-rates in growth stocks
10:45 – Frazis Capital’s auto plays (Carvana – NYSE:CVNA, Tesla – NASDAQ:TSLA)
12:45 – Changing attitudes to public transport because of COVID-19
13:40 – Where does the common cold come from?
14:10 – Market darlings showing some cracks, including Nanosonics (ASX:NAN)
14:50 – Afterpay’s (ASX:APT) European acquisitions
15:55 – Xero’s (ASX:XRO) acquisition of an invoice-lending company
17:20 – Great companies create much bigger TAMs than first estimates
Chris Gosselin from Australian Fund Monitors (https://www.fundmonitors.com/landing.php) interviewed us about the fund and strategy.
0:00 - Introducing Michael Frazis
1:12 - Michael introduces Frazis Capital and describes its core investment requirements (Customer love, explosive growth and market leadership)
2:45 - The opportunity presented by high growth companies with ugly financial statements, professional scepticism and high short interest
4:00 - The best investment opportunities are often in front of your eyes the entire time
4:35 - Michael reiterates the importance of the fund's core investment requirements
6:10 - Unit economics often tell a very different and more valuable story than financial statements (using Xero and Tesla as examples)
7:35 - Frazis Capital's systematic framework
9:30 - Chris asks Michael, "When you don't get it right, how do you manage that?"
12:00 - Chris asks Michael, "Is there a stage at which these companies, which are growing very quickly, become mature?"
12:40 - Michael discusses Adobe and Salesforce as examples of mature software companies
14:50 - The importance of focusing on market leaders, using the example of the BNPL industry
16:10 - MercadoLibre and Sea - true market leaders, which deserve valuation premiums
18:00 - Focusing on $5-20 billion companies growing revenue at 50-100%/annum
18:40 - Chris and Michael discuss the headwinds and opportunities presented by COVID-19
20:10 - Making sure that portfolio holdings are accelerating through the coronavirus period
22:00 - What is the smart move right now? Find companies with pent-up demand
Companies with brilliant products and broad customer support are faring significantly better than mature incumbents.
One of the fund's newest holdings satisfies our three core criteria: Exponential growth, products that customers truly love, genuine market leadership.
Gaming is one of the more exciting industries in technology right now. We discuss the opportunities and precedents for Twitch and streaming phenomenon.
Ben also takes us through leading chipmakers like NVDIA.
0:32 - Long term trends for Nvidia
2:16 - Demand for Nvidia GPU's in Data centres
3:03 - Use of Nvidia chips for Crypto mining
4:38 - Semiconductors are on the forefront for everything
5:46 - Nvidia compared to other chip makers, AMD and Intel
8:35 - Bitcoin mining economics
9:22 - Technology companies that 'miss the trend'
10:40 - Moore's Law and what it means for CPU's and GPU's
11:58 - What is the go-to for gamers now?
12:50 - Interesting stocks and opportunities for gaming - the shift to mobile gaming
15:35 - American vs Chinese Mobile games
16:10 - Sea's mobile game Freefire's recent success
18:40 - Ben's experience with mobile gaming
19:44 - Popularity of the MOBA category specifically League of Legends
21:05 - Online viewership of League of Legends worlds more than 44M concurrent
22:06 - Streaming as a platform for advertising games (Twitch, Mixer)
24:42 - Reddit gold - 100,000's donations add up
25:15 - Facebook hate speech fiasco
26:42 - Radicalisation of people through the Youtube algorithm
27:52 - TicTok's censorship and radicalisation
29:36 - Thoughts on gaming stocks (Activison, EA)
31:04 - IP conversion from console to Mobile
31:57 - Hit vs franchise games
34:30 - Microsofts unsuccessful move into the streaming industry
36:44 - Chinese apps and consumer trends moving to the US
38:16 - Thoughts on 3D gaming and where gaming will be in 5 years
39:46 - Historical precedence for streaming Chess on Twitch
Peter Stevens rejoins us to discuss some of our environmentally friendly investments.
0:30 - The continued dispersion between technology and the rest of the market
0:50 - The successes of Pinduoduo, Carvana and Afterpay
1:28 - Frazis Capital's successful diversification away from a highly concentrated portfolio
2:33 - Comparing today's hot tech businesses with the hot auto businesses of the past
3:00 - Michael introduces Plug Power (NASDAQ:PLUG), a hydrogen fuel cell manufacturer and one of the fund's most exciting holdings
5:00 - Introducing the Frazis Capital Youtube channel
5:50 - Michael introduces Chinese software firm, Kingsoft Corporation (HKG:3888)
7:00 - Peter and Michael discuss the various factors influencing the systematic underpricing of IPOs
10:10 - Cochlear's (ASX:COH) lucrative discounted capital raising
11:35 - The value that Frazis Capital can add to your portfolio
12:40 - Solaredge (NASDAQ:SEDG), an innovative Israeli solar provider and portfolio position
14:40 - ESG investing and the importance of being forward-looking
Alexander began his career investing in technology for UK funds management giant Neptune, before joining London-based VC fund Redline Capital. It's rare indeed to speak to someone with experience across the public and private side of tech investing.
We had a fascinating chat covering robotic process automation, innovation investing, and life in venture capital vs public markets.
https://www.linkedin.com/in/alexander-portz-3a265236/
https://www.redline-capital.com/
0:50 - Alex talks about his start in public markets
2:30 - Tech investing at Neptune Capital
3:50 - Alex discusses a high-performing company during his time at Neptune
6:20 - Michael and Alex discuss a stand-out semiconductor manufacturer
8:05 - The importance of investing in high quality companies
9:25 - Investing using an EV/Sales ratio and sales growth (Shopify as an example)
9:50 - The opportunity presented by Blue Prism
10:00 - Alex and Michael extensively discuss Blue Prism
15:05 - Alex outlines his firm's investment in Catalytic, an innovative 'SAAS-linker'
18:10 - How Alex is finding the change between public markets and venture capital (VC)
20:40 - Carrying out due diligence on a VC deal compared to public markets research (sourcing, sector research etc)
23:05 - The incentives of public companies' management to always be positive
25:45 - How Alex splits his time within VC
29:20 - Some exciting thematics, such as quantum computing
30:55 - The concept of Moore's law
33:00 - The highest quality sources of learning in quantum computing
34:24 - The opportunity in mental health software such as Catasys
36:50 - Expensive data paid for by hedge funds
39:30 - The importance of reviewing companies' real-time data before the rest of the market
41:10 - Some useful data points that can be gathered from LinkedIn
42:40 - Alex's recent public markets' investments in high growth SAAS
44:00 - Michael outlines the fund's recent strategy of buying coronavirus 'recovery plays'
47:10 - Are MongoDB and Shopify overvalued?
49:50 - Alex discusses his positive outlook on lithium
52:00 - Michael and Alex reminisce on their scientific research projects at Oxford
Eti Amegor of Axius Partners & www.suitsandkicks.com joins us to talk allocating and investing in the strange current environment.
0:52 - Opportunities during the coronavirus
1:55 - Current investor trends regarding liquidity
3:30 - The new private equity fund being launched by Eti's firm
6:30 - Why the coronavirus is the best environment for active investment managers
8:00 - Life Sciences stocks and the coronavirus
9:30 - Mike talks through Moderna, which focuses on drug discovery and development based on messenger RNA
10:50 - Eti and Mike talk Afterpay (again)
14:00 - The endgame... Afterpay vs Paypal
16:55 - Why Frazis Capital does not buy Big Tech
17:10 - Mike introduces MercadoLibre, a new portfolio holding
18:30 - Mike introduces Sea, another new portfolio holding
20:00 - Shopify has performed superbly... is it still worth the valuation?
23:55 - Investment thematics within Frazis Capital Partners
25:20 - Mike discusses three digital health investment opportunities
28:30 - Frazis Capital's recent approach to a more diversified portfolio construction
34:30 - The fund's approach to adding new positions to the portfolio
37:10 - The underperformance of 70+ stock portfolios
41:00 - The issues that fund managers face when running highly consolidated portfolios
43:50 - Why Eti believes that Frazis Capital is in the 'sweet spot'
52:00 - Frazis Capital's up and coming webinar
Peter Stevens joins us to talk about the market sell-off, how we're positioned, and interesting opportunities that we've found.
If you'd like to know more about us see:
www.fraziscapitalpartners.com
Peter writes his own market commentary here:
https://insufficientcapital.com/
0:24 – Peter wipes away his tears
0:50 – There’s growth and then there’s growth (e.g. Afterpay vs Zip)
1:30 – Why you should pay up for quality businesses
2:17 – Illiquidity during sell-offs
2:50 – Electro Optic Systems (ASX:EOS), a great business that does not fit ESG criteria
3:35 – Analysing quality within the WAAAX (the Australian equivalent of the FAANG)
4:54 – Frazis Capital’s avoidance of education and tourism stocks
5:50 – Peter and Michael look at Qantas (ASX:QAN), Australia’s major airline
7:40 – Theoretically maintaining a 20% cash position
8:00 – Michael discusses Ray Dalio’s “Principles”
9:25 – Carvana (NYSE:CVNA), Frazis Capital’s largest coronavirus casualty
10:22 – Afterpay’s (ASX:APT) accelerating growth and Frazis Capital’s internal forecasts
11:40 – Afterpay’s US in-store opportunity
12:30 – The benefits of an equities/treasuries strategy over popular options strategies
13:43 – Global stimulus packages and expansionary monetary policy
14:13 – Renewable energy businesses and how they may benefit from stimulus packages
14:45 – Twist Bioscience (NASDAQ:TWST), a well-performing Frazis Capital position
15:30 – Viruses tend to become less dangerous with time because of evolutionary pressures
16:55 – Gilead’s (NASDAQ:GILD) antiviral drug and the coronavirus
17:25 – Some Aussie smallcaps touting business expansion into virus-induced growth industries (e.g. hand sanitizers, diagnostics)
18:30 – The panic in supermarkets parallels the panic on markets
19:08 – “Buy when there is blood in the streets” (Baron Rothschild) and its relevance to this sell-off
19:25 – The origins of Rothschild’s famous blood in the streets quote
20:45 – Frazis Capital portfolio construction during the coronavirus sell-off
21:55 – Zoom’s (NASDAQ:ZM) coronavirus rally and its rich valuation
23:00 – Peloton (NASDAQ:PTON) and Carnival (NYSE:CCL), two stock picks from NYU Professor, Scott Galloway
Three things you didn't know about the the virus, an Aussie company that stands to benefit, and two in the United States. Afterpay's results... this was a quick one, but a good one.
If you'd like to know more about us see:
www.fraziscapitalpartners.com
You can find Claude at
www.arichlife.com.au
0:50 – Michael gives an update on the underlying science of the latest coronavirus
1:44 – The importance of understanding the spike protein
2:05 – Why the coronavirus is so much more infectious than SARS
3:14 – Claude shares his thoughts on how the spread of the coronavirus may play out
3:30 – Michael discusses the recent coronavirus tests using SARS antibodies
5:02 – Claude reveals his plan of action if Australian coronavirus transmission increases
6:20 – Discussion of Swine Flu
7:30 – The issue with unpredictable virus mutation
9:30 – The effects of temperature on the coronavirus
11:00 – Discussion of Biotron (ASX:BIT), an Australian biotech which could combat coronavirus
11:23 – Claude discusses his position in Teledoc (NYSE:TDOC), a company benefiting from the coronavirus
15:16 – Portfolio performance during sell-offs and the resilience of the healthcare sector
16:50 – Afterpay (ASX:APT) results discussion
21:10 – The coronavirus sell-off, a glitch in the long-term charts
23:00 – How systematic trading in markets exaggerates moves
Episode 23: Time to sell? Mike and Claude go through EML, Shopify, Wisetech and other cult stocks in the market right now.
If you'd like to know more about us see:
www.fraziscapitalpartners.com
1:08 - Michael and Claude discuss EML Payments (ASX:EML)
1:44 - The ethical dilemma of EML’s gambling exposure
2:40 - Problems relating to the sale high growth stocks
3:16 - EML’s acquisition of Prepaid Financial Services
3:44 - Accusations from Ownership Matters concerning EML
6:50 - The issue with ‘EBITDA’ as a financial metric
9:05 - Michael and Peter Stevens’ thoughts on EML
10:03 - The long-term threat for EML
10:50 - The macroeconomic impact of the coronavirus
12:10 - Does coronavirus’ growing risk as a pandemic change Frazis Capital’s view of market conditions?
13:45 - Chinese stimulus countering the impacts of the coronavirus
15:35 - Luxury brands negatively impacted by the coronavirus as shopping numbers fall
16:58 - Many Australian technology businesses are still trading at high multiples of sales
18:14 - Michael and Claude discuss Shopify (NYSE:SHOP) and its lofty valuation
22:08 - The global ecommerce opportunity for Shopify
23:30 - The only way to guarantee outstanding returns in fast-growing, high quality businesses like Shopify
25:40 - The pressure to sell Shopify and Frazis Capital’s long-term vision for the company
27:01 - The mentality of never buying at a higher price than a previous sell price
28:20 - Claude discusses his investment in Chant West (ASX:CWL)
29:38 - Chant West’s sale of its business for nearly double the market capitalisation at the time
30:33 - Microcaps more trouble than they are worth?
31:30 - Why Australian smallcap fund managers outperform
33:50 - Why Frazis Capital prefers companies with larger capitalisations
34:38 - People who have left the company and customers are the most useful insights into company dynamics
35:40 - Claude spends a huge amount of time researching the people involved in corporate Australia
37:00 - Frazis Capital’s thoughts on Wisetech (ASX:WTC) and its growth through acquisition
39:20 - J Capital raising questions about Wisetech’s accounting practices
41:25 - Issues regarding Wisetech’s streamlining of products as acquisitions roll in
42:00 - Claude’s failed investment in Vista Group (ASX:VGL)
43:10 - The long-term benefit of being long-only
Mike and Claude from A Rich Life (https://arichlife.com.au/) talk Australian growth stocks for the next decade.
If you'd like to know more about us see:
www.fraziscapitalpartners.com
0:38 - Claude's background and time at Motley Fool
4:30 - Pro Medicus (PME:ASX) recommendation and discussion
6:38 - Claude touches on his investment style
8:08 - Pro Medicus as a platform business rather than just a software business
8:30 - Pro Medicus - the numbers
10:20 - Claude dives into Pro Medicus' two key revenue streams
11:50 - Michael introduces Alteryx (AYX:NYSE) and accounting standards
14:45 - Claude's worst mistake (Touchcorp)
17:30 - Claude touches on cognitive errors
18:10 - Michael discusses Afterpay (APT:ASX), comparing it to some US tech investments
19:25 - Afterpay, the YOLO stock?
21:55 - The network effects of Afterpay
22:30 - Consumer behaviour of Afterpay customers
24:38 - Claude introduces Avita Healthcare (AVH:ASX), discussed in Frazis Capital's previous podcast
26:58 - Avita's opportunity in vitiligo and skin rejuvenation
29:59 - How to value a company like Avita when there are no conventional cashflows?
32:02 - When should you sell a company like Avita?
35:20 - BARDA's funding of Polynovo (PNV:ASX) and Avita
37:40 - Claude goes through Audinate (AD8:ASX)
41:55 - Audinate's financial numbers
45:00 - Audinate's next 5 years
48:00 - Claude talks about his new project, "A Rich Life"
Matthew Shribman has accumulated over 25 million views across platforms for his 'Science in the Bath' series, available here: https://www.youtube.com/channel/UCoSRNBi6F4jN0CYq-sRcOHQ
We talk about how birds literally 'see' the Earth's magnetic field, and cover Twist Bioscience, a company that's revolutionizing gene synthesis. Twist is working on DNA as a viable storage medium for computers, drug discovery, genetic sequencing and synthetic biology. This is a little more sciencey than usual, but I think you will enjoy!
If you'd like to know more about us see:
www.fraziscapitalpartners.com
Timestamps:
0:11 -- Introducing Matthew Shribman
3:00 -- Whale carbon sequestration
4:30 -- Matthew's bird migration project at Oxford
6:50 -- How bird compasses work
9:03 -- How to photograph molecules with lasers, prisms and mirrors
15:49 -- Our new investment in Twist - revolutionizing DNA synthesis
17:53 -- Twist's take on drug development
19:08 -- DNA as a storage medium for computers
24:33 -- Weather patterns & climate explained
27:02 -- The PT extinction event
27:45 -- Pension funds and ESG investing
28:29 -- Coal & the broader energy sector getting hit twice
31:00 -- The inefficiencies of "QWERTY" keyboards
36:57 -- Synthetic biology for fuel
40:33 -- Discussion on nuclear & its safety
41:55 -- Israeli innovation for energy storage
44:08 -- Science innovation coming out of Oxford
Peter Stevens joins us to discuss Coronavirus and two Aussie burns innovators: Avita and Polynovo. Find more information about us here: www.fraziscapitalpartners.com And please get in touch if you have questions you'd like us to answer on the podcast, suggestions or feedback.
If you'd like to know more about us see:
www.fraziscapitalpartners.com
00:28 – Coronavirus, and how to calculate the real mortality rate
02:20 – The common cold is a coronavirus
04:18 – Market performance during past pandemics
05:00 – Why you shouldn’t sell your stocks because of the coronavirus!
07:00 – Australian bushfiresand two Aussie burns innovators
07:50 – Introducing Polynovo (ASX:PNV) and how the firm’s improving the existing standard-of-care for serious burns over the incumbent, Integra
14:40 – Avita (ASX:AVH)
15:12 – Avita's RECELL system
16:16 – How ReCell improves recovery
17:10 – The opportunity in Vitiligo
19:12 – Skin grafts
19:47 – How Avita fits within our focus on customer love
20:45 – Avita’s opportunity in skin rejuvenation opportunity
22:40 – Australian life sciences successes of the past
25:10 – The real value uplift opportunity in life sciences
26:50 – More customer love!
27:18 – Avita and Polynovo's cash situation
28:40 – Mesoblast
30:50 – Bitcoin, the life sciences, and tying it all together.
Peter Stevens rejoins us to discuss investment strategy and our top new picks.
If you'd like to know more about us see:
www.fraziscapitalpartners.com
1:00 – Recap of 2019; how shorts hampered performance and the stocks that went well
3:58 – Why doing less is a key lesson
5:58 – Where Frazis Capital sits in portfolios
8:06 – How companies like Xero and Afterpay shot the lights out and how investors can find the next 20-baggers
14:14 – Michael Frazis’s background
17:30 – The only ‘real way’ to make money
18:46 – 3 most exciting companies in the Frazis portfolio
20:34 – The thesis for investing in life sciences companies
Peter Stevens joins us to talk about some of our long held investments and latest new ideas. Peter Stevens has rejoined Frazis Capital Partners, and writes his own market blog here: https://insufficientcapital.com/
If you'd like to know more about us see:
www.fraziscapitalpartners.com
A wide-ranging conversation with Eti Amegor, of Axius Partners.
We discuss growth investing, Carvana and our top biotech picks, including a drug to reduce stress.
Eti runs a podcast himself and asked some tough questions! This one was a lot of fun.
Eti's podcast 'Suits and Kicks' is available here: https://podcasts.apple.com/au/podcast/suits-and-kicks/id1454889632
If you'd like to know more about us see:
www.fraziscapitalpartners.com
Paul Brennan is a markets veteran with over 20 years at Citigroup in Australia, most recently as Chief Economist. He now consults for a wide range of clients, and in his spare time, offers his expertise to university students. It's always great to have a chat with someone who measures their market experience in decades, so this was a real privilege. We go deep on economics, the Australian economy, what it was like in the 90s and where things might be going next.
If you'd like to know more about us see:
www.fraziscapitalpartners.com
Paul Brennan can be found here:
https://au.linkedin.com/in/paulbrennanassociates
Peter Stevens joins us to talk about the recent growth sell off and the new opportunities and investment ideas we're looking at.
If you'd like to know more about us see:
www.fraziscapitalpartners.com
There are many ways to create value without showing after-tax profits. Michael Frazis and Mario Emmanuel discuss new approaches. https://www.fraziscapitalpartners.com/post/value-is-dead-long-live-value
Recorded 16 September, 2019, this podcast features Anna Satouris and a discussion around energy, markets and prices.
Michael Frazis and Anna Satouris discuss Carvana, Afterpay, Pinduoduo and our recent fee rebate to long term clients.
This episode features a chat with Rebecca Gingell, who runs business development at OxMet Technologies, an Oxford University spin-out utilizing decades of academic modelling expertise to design and commercialize new alloys.
It turns out that almost every alloy we use in every day life was discovered long ago.
Rebecca explains how we've barely scratched the surface of the potential number of alloys, and shares some interesting facts, like why it's not actually strength that you should optimise for when designing medical alloys for bone implants.
More information on OxMet is available here:
https://www.oxmet-technologies.com/
And Becky can be contacted here:
https://www.linkedin.com/in/rebecca-gingell/
In this episode we recorded a fascinating chat with Hon Weng Chong, the founder CC Labs.
Hon Wen first rose to fame as a cofounder of Clinicloud, an innovative medical devices company that won FDA approval.
The firm was originally backed by Tencent and Ping An, and is now developing a new form of computing: instead of using silicon chips, they are growing live self-organising networks of neurons. They're not simulating neurons, they're actually growing them.
The technology could be applied to some of the toughest targets in artificial intelligence, and Hon's plan is to take this one step further, and put the entire computational platform on the cloud, so researchers around the world can run novel, live experiments on CC Lab's wet infrastructure.
This is cutting edge stuff, so if you want to know more or help in any way please get in touch or reach out to Hon Wen directly.
More information available here:
www.cclabs.ai
In this episode we have a chat with Eti Amegor, director of Axius Partners and founder of Suits and Kicks ( http://www.suitsandkicks.com/ ).
At Axius, Eti advises and raises capital for some of the most distinguished and highest returning investment funds in the world.
We discuss innovation and disruption in technology, and the role of hedge funds in a portfolio.
We discuss the market outlook, Disney's new streaming service and portfolio protection.
Michael Wayne is the founder of the Medallion Financial Group, a wealth management firm specialising in investment advice.
Michael discusses his firm, some investment ideas, and the outlook for financial markets, as well as Biogen's latest Alzheimer's trial failure in biotech land.
More information on Medallion and Michael Wayne can be found here:
https://www.medallionfinancial.com.au/
Michael Frazis and Harvey Migotti discuss Google, IPG Photonics and Carvana.
Harvey has a background in both public and private market investing, with roles at Balyasny, Amiya and Apax.
https://www.fraziscapitalpartners.com/
Michael Frazis and Eti Amegor go deep into volatility, why the beginning and end of 2018 were so different, and where Australian investors are putting their money.
Eti also talks about his blog Suits and Kicks, for high achieving professionals who want to perform at the highest level both inside and outside the office.
Available here:
http://www.suitsandkicks.com/
Michael Frazis and Anna Satouris discuss Afterpay, Cooper Energy, Stanmore Coal and the Australian housing market.
Michael Frazis and Mario Emmanuel discuss financial markets in 2018, the current outlook, and some of our latest investments.